Keywords
non-typhoidal salmonella, NTS, antibody, Uganda
non-typhoidal salmonella, NTS, antibody, Uganda
Invasive non-typhoidal Salmonella (iNTS) disease is principally caused by serovars S. Typhimurium and S. Enteritidis and is thought to be responsible for up to 680,000 deaths annually, with Africa accounting for more than half of cases1. Much of this burden is in children under 5 years and HIV-infected adults. In view of this major global burden of disease, and rapid emergence of multidrug resistant iNTS strains2, development of a vaccine is increasingly vital3.
Studies in Malawian children indicate that anti-S. Typhimurium antibodies, notably IgG to O-antigen of LPS and flagellin, and serum bactericidal activity rises rapidly with age in the first few years of life corresponding with a fall in cases of iNTS disease4,5. One study found a positive correlation between serum bactericidal assay (SBA) killing and acquisition of anti-LPS IgG5. However, there is no standardised assay for measurement of iNTS-specific IgG, and the clinical significance of the iNTS SBA is unknown. Given that incidence of iNTS disease drops in children over 2 years, it has been suggested that a rise in specific antibodies and bactericidal activity correlates with protection. This hypothesis is complicated by the observation that among HIV-infected Malawian adults, high LPS-specific IgG was associated with a lack of in vitro bacterial killing6.
In a cross-sectional study, we investigated NTS-specific antibody responses in the rural Ugandan General Population Cohort (GPC)7. Levels of IgG against serovars S. Typhimurium and S. Enteritidis LPS O-antigens were measured using a standardised in-house ELISA in stored sera from a cross-section of 1,090 Ugandans of all ages, 10 of whom were HIV-infected. Sera from adults (≥ 16 years) were collected from January 2014 to November 2015, and children (<16 years) from January 2016 to November 2017. Antibody units (AU) were calculated using Gen5 software (version 2.0) using a five-parameter logistic (5PL) curve generated with a standard serum from an iNTS-exposed individual. Sera were defined as seronegative if below the lower limit of detection (4 AU for S. Typhimurium and 5 AU for S. Enteritidis) at 1:100 serum dilution.
Written informed consent for the use of clinical records and biological samples for research purposes was obtained from all GPC participants following Uganda National Council of Science and Technology guidelines. Ethical approval for the use of samples for this study was obtained from The UVRI Research and Ethics Committee and from the Uganda Council for Science and Technology (Ref: GC/127/19/10/710).
In this assay, overall O-antigen seropositivity was 82% for S. Typhimurium, and was 70% for S. Enteritidis. Levels of antibody were undetectable in at least 50% of children until 18 months for both serovars and a similar pattern of increasing IgG level was observed with increasing age (Figure 1A, B). There were no observable differences in antibody levels by sex (Figure 1C, D). HIV-infected individuals did not have notably high IgG antibody responses, although the study was not powered to demonstrate this.
Plots showing antibody units (AU) for S. Typhimurium (A and C) and S. Enteritidis (B and D) by age. Orange dots indicate HIV infected individuals. (A, B). Females are indicated in red and males in blue (C, D). The box shows the interquartile range (IQR) with middle line representing the median. The whiskers represent the adjacent values, defined as 1.5 × IQR from the edge of the box, with values outside this range shown individually. LLOQ, lower limit of quantification.
Although performed using a flow cytometric assay, previously published data from Malawi suggest that NTS-specific IgG is present in the majority of children throughout infancy4, contrasting with our results from Uganda. This could be due to variation in exposure to iNTS in Uganda compared to Malawi, or differences in assays. However, burden of, and exposure to, iNTS disease in Uganda is not well understood. A standardised assay is key to understanding variation in exposure across geographic locations to support vaccine development.
Open Science Framework: Invasive Non-Typhoidal Salmonella serology in Uganda. https://doi.org/10.17605/OSF.IO/68BYT8.
This project contains the age, sex, antibody levels, HIV status and Salmonella status of each participant.
Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
This work was supported by the UK Medical Research Council (MRC): grant number MR/ J003999/1 to LS, grant number MR/K012126/1 to SN, and the Bill and Melinda Gates Foundation (BMGF): grant number OPP1148489 to CM. The Ugandan General Population Cohort study is jointly funded by the UKMRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
Gates Open Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Enteric disease, vaccinology, immunology
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
References
1. Fiorino F, Rondini S, Micoli F, Lanzilao L, et al.: Immunogenicity of a Bivalent Adjuvanted Glycoconjugate Vaccine against Salmonella Typhimurium and Salmonella Enteritidis.Front Immunol. 2017; 8: 168 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Infectious disease, bacterial vaccine development, humoral immunity
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Yes
References
1. MacLennan CA, Gondwe EN, Msefula CL, Kingsley RA, et al.: The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children.J Clin Invest. 2008; 118 (4): 1553-62 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Infectious diseases, antibody responses, epidemiology, vaccines
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Salmonella infection and vaccine development, polysaccharide vaccine, bacteria-derived nanoparticle vaccine.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Version 1 26 Jun 19 |
read | read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Register with Gates Open Research
Already registered? Sign in
If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research.
We'll keep you updated on any major new updates to Gates Open Research
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)